NCT05696847

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 6 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Tirzepatide	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2023-02-07
• Primary completion: 2025-01-16
• Completion: 2025-01-16
• First posted: 2023-01-25
• Last updated: 2025-08-26
• Results posted: 2025-08-26

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study